Structure Therapeutics (GPCR) Competitors

$36.87 +0.99 (+2.76%)

Closing price 05/20/2026 04:00 PM Eastern

Extended Trading

$37.56 +0.69 (+1.87%)

As of 05:27 AM Eastern

GPCR vs. RDY, ARWR, ABVX, CYTK, and PRAX

Should you buy Structure Therapeutics stock or one of its competitors? MarketBeat compares Structure Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Structure Therapeutics include Dr. Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), Abivax (ABVX), Cytokinetics (CYTK), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Structure Therapeutics (NASDAQ:GPCR) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Structure Therapeutics presently has a consensus target price of $109.25, indicating a potential upside of 196.31%. Dr. Reddy's Laboratories has a consensus target price of $16.90, indicating a potential upside of 24.13%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Structure Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 5.6% of Structure Therapeutics shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Structure Therapeutics had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 10 mentions for Structure Therapeutics and 4 mentions for Dr. Reddy's Laboratories. Structure Therapeutics' average media sentiment score of 0.80 beat Dr. Reddy's Laboratories' score of 0.02 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Structure Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.16% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%

Structure Therapeutics has a beta of -1.31, suggesting that its stock price is 231% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Dr. Reddy's Laboratories	$3.58B	3.17	$484.20M	$0.58	23.47

Summary

Structure Therapeutics and Dr. Reddy's Laboratories tied by winning 8 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Arrowhead Pharmaceuticals?

Structure Therapeutics (NASDAQ:GPCR) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 5.6% of Structure Therapeutics shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Structure Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Structure Therapeutics' return on equity of -24.91% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Structure Therapeutics currently has a consensus price target of $109.25, suggesting a potential upside of 196.31%. Arrowhead Pharmaceuticals has a consensus price target of $87.80, suggesting a potential upside of 13.82%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Structure Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

Structure Therapeutics has a beta of -1.31, meaning that its share price is 231% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Structure Therapeutics. MarketBeat recorded 18 mentions for Arrowhead Pharmaceuticals and 10 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.80 beat Arrowhead Pharmaceuticals' score of 0.56 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Arrowhead Pharmaceuticals	$829.45M	13.10	-$1.63M	-$2.15	N/A

Summary

Structure Therapeutics beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Abivax?

Structure Therapeutics (NASDAQ:GPCR) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Structure Therapeutics currently has a consensus price target of $109.25, suggesting a potential upside of 196.31%. Abivax has a consensus price target of $137.15, suggesting a potential upside of 14.39%. Given Structure Therapeutics' higher possible upside, research analysts clearly believe Structure Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Structure Therapeutics has a beta of -1.31, indicating that its share price is 231% less volatile than the broader market. Comparatively, Abivax has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Structure Therapeutics' return on equity of -24.91% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Abivax	N/A	-146.43%	-88.69%

Structure Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A

In the previous week, Structure Therapeutics had 7 more articles in the media than Abivax. MarketBeat recorded 10 mentions for Structure Therapeutics and 3 mentions for Abivax. Structure Therapeutics' average media sentiment score of 0.80 beat Abivax's score of -0.09 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 5.6% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Structure Therapeutics beats Abivax on 10 of the 13 factors compared between the two stocks.

How does Structure Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Structure Therapeutics (NASDAQ:GPCR) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

91.8% of Structure Therapeutics shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 5.6% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cytokinetics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.31, suggesting that its stock price is 231% less volatile than the broader market.

Structure Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Structure Therapeutics	N/A	-24.91%	-23.67%

Structure Therapeutics has lower revenue, but higher earnings than Cytokinetics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	111.33	-$784.96M	-$6.84	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

In the previous week, Cytokinetics had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 11 mentions for Cytokinetics and 10 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.80 beat Cytokinetics' score of 0.49 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics currently has a consensus target price of $99.30, suggesting a potential upside of 26.06%. Structure Therapeutics has a consensus target price of $109.25, suggesting a potential upside of 196.31%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Structure Therapeutics beats Cytokinetics on 10 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Structure Therapeutics (NASDAQ:GPCR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Structure Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Structure Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,094.36	-$303.27M	-$13.37	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Praxis Precision Medicines has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.31, meaning that its share price is 231% less volatile than the broader market.

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Structure Therapeutics' return on equity of -24.91% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Structure Therapeutics	N/A	-24.91%	-23.67%

Praxis Precision Medicines presently has a consensus price target of $592.67, indicating a potential upside of 76.59%. Structure Therapeutics has a consensus price target of $109.25, indicating a potential upside of 196.31%. Given Structure Therapeutics' higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

In the previous week, Structure Therapeutics had 6 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 10 mentions for Structure Therapeutics and 4 mentions for Praxis Precision Medicines. Structure Therapeutics' average media sentiment score of 0.80 beat Praxis Precision Medicines' score of 0.29 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Structure Therapeutics beats Praxis Precision Medicines on 9 of the 14 factors compared between the two stocks.

Get Structure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GPCR vs. The Competition

Export

Metric	Structure Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.54B	$3.27B	$6.30B	$12.11B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-42.38	18.42	20.82	25.32
Price / Sales	N/A	273.39	526.01	71.05
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	1.80	6.81	9.91	6.94
Net Income	-$141.20M	$24.18M	$3.55B	$335.25M
7 Day Performance	-7.45%	-1.57%	-0.77%	-1.39%
1 Month Performance	-21.27%	-2.57%	-1.13%	0.09%
1 Year Performance	52.67%	60.75%	33.75%	32.51%

Structure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GPCR Structure Therapeutics	3.353 of 5 stars	$36.87 +2.8%	$109.25 +196.3%	+49.5%	$2.54B	N/A	N/A	136
RDY Dr. Reddy's Laboratories	3.5646 of 5 stars	$13.15 -0.6%	$16.90 +28.6%	-6.0%	$11.04B	$3.81B	17.07	27,811
ARWR Arrowhead Pharmaceuticals	2.3314 of 5 stars	$77.74 +6.9%	$84.90 +9.2%	+373.5%	$10.24B	$829.45M	N/A	400
ABVX Abivax	2.9389 of 5 stars	$122.13 -0.5%	$137.15 +12.3%	+1,967.2%	$9.73B	N/A	N/A	61	Upcoming Earnings
CYTK Cytokinetics	2.7451 of 5 stars	$74.56 -3.1%	$97.45 +30.7%	+141.2%	$9.57B	$88.04M	N/A	250	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GPCR) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Structure Therapeutics (GPCR) Competitors

GPCR vs. RDY, ARWR, ABVX, CYTK, and PRAX

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Structure Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Structure Therapeutics compare to Abivax?

Summary

How does Structure Therapeutics compare to Cytokinetics?

Summary

How does Structure Therapeutics compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Structure Therapeutics (GPCR) Competitors

GPCR vs. RDY, ARWR, ABVX, CYTK, and PRAX

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Do analysts rate GPCR or RDY?

Do insiders & institutionals believe in GPCR or RDY?

Does the media favor GPCR or RDY?

Is GPCR or RDY more profitable?

Which has more risk & volatility, GPCR or RDY?

Which has preferable earnings & valuation, GPCR or RDY?

Summary

How does Structure Therapeutics compare to Arrowhead Pharmaceuticals?

Do insiders and institutionals believe in GPCR or ARWR?

Is GPCR or ARWR more profitable?

Do analysts prefer GPCR or ARWR?

Which has more risk & volatility, GPCR or ARWR?

Does the media favor GPCR or ARWR?

Which has preferable valuation and earnings, GPCR or ARWR?

Summary

How does Structure Therapeutics compare to Abivax?

Do analysts rate GPCR or ABVX?

Which has more volatility and risk, GPCR or ABVX?

Is GPCR or ABVX more profitable?

Which has stronger earnings and valuation, GPCR or ABVX?

Does the media prefer GPCR or ABVX?

Do insiders & institutionals hold more shares of GPCR or ABVX?

Summary

How does Structure Therapeutics compare to Cytokinetics?

Do insiders and institutionals hold more shares of CYTK or GPCR?

Which has more volatility & risk, CYTK or GPCR?

Is CYTK or GPCR more profitable?

Which has preferable earnings and valuation, CYTK or GPCR?

Does the media refer more to CYTK or GPCR?

Do analysts recommend CYTK or GPCR?

Summary

How does Structure Therapeutics compare to Praxis Precision Medicines?

Which has better earnings and valuation, PRAX or GPCR?

Which has more volatility and risk, PRAX or GPCR?

Do insiders & institutionals believe in PRAX or GPCR?

Is PRAX or GPCR more profitable?

Do analysts recommend PRAX or GPCR?

Does the media prefer PRAX or GPCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools